Get the Stockscreener App
4.19
5.01%
0.20
Cingulate Inc stock is traded at $4.19, with a volume of 131.39K.
It is up +5.01% in the last 24 hours and down -26.88% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$3.99
Open:
$4.02
24h Volume:
131.39K
Relative Volume:
0.82
Market Cap:
$22.06M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1285
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
+3.71%
1M Performance:
-26.88%
6M Performance:
-1.87%
1Y Performance:
-63.05%
1-Day Range:
$3.9525
$4.19
1-Week Range:
$3.71
$4.21
52-Week Range:
$3.02
$11.88
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.19 | 21.41M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate price target lowered to $10 from $11 at Roth Capital - TipRanks
Cingulate places CEO Schaffer on administrative leave - MSN
Cingulate Inc. Reports Q2 2025 Financial Results - TipRanks
Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year - MSN
Cingulate Inc. SEC 10-Q Report - TradingView
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights - The Manila Times
Cingulate Inc. Submits New Drug Application for Lead Asset CTx-1301, Anticipates FDA Decision in Q4 2025 - AInvest
Novel Once-Daily ADHD Drug Shows Full-Day Efficacy: Cingulate Submits FDA Application for CTx-1301 - Stock Titan
Cingulate Installs Interim Leadership After CEO Put On Administrative Leave - insights.citeline.com
Cingulate Inc CEO Shane Schaffer on Administrative Leave - MSN
What risks could impact Cingulate Inc. Equity Warrant stock performanceQuarterly Portfolio Report & Weekly High Conviction Trade Ideas - beatles.ru
Why Cingulate Inc. stock attracts strong analyst attentionPortfolio Risk Summary & Weekly Top Gainers Alerts - thegnnews.com
Quant Tools Rank Cingulate Inc. as High Risk High RewardJuly 2025 Review & Daily Volume Surge Trade Alerts - classian.co.kr
What’s the MACD signal for Cingulate Inc. Equity WarrantJuly 2025 Decliners & AI Powered Market Entry Ideas - thegnnews.com
Cingulate Inc. Delays Q2 Financial Report Filing Due to Management Changes. - AInvest
Cingulate Inc. Delays Quarterly Report Filing - MSN
Sector Leaders Rotate Capital Into Cingulate Inc.2025 Top Gainers & Real-Time Chart Breakout Alerts - 선데이타임즈
Cingulate Inc. Tests 50 Day MA After Sharp DeclineJuly 2025 Levels & Technical Buy Zone Confirmation - newsimpact.co.kr
KC company puts CEO on leave days after second domestic battery arrest - yahoo.com
Cingulate puts CEO on leave days after second domestic battery arrest - The Business Journals
Is This a Bottoming Phase for Cingulate Inc.Market Activity Summary & Community Consensus Trade Alerts - 선데이타임즈
Cingulate places CEO Shane Schaffer on leave, appoints interim leadership By Investing.com - Investing.com Nigeria
Cingulate Places CEO Shane Schaffer on Administrative Leave - MarketScreener
Cingulate places CEO on leave, appoints interim leadership By Investing.com - Investing.com Nigeria
Cingulate places CEO on leave, appoints interim leadership - Investing.com
Cingulate Inc. Appoints Jennifer Callahan, Chief Financial Officer to Serve as Interim Chief Executive Officer, Effective August 14, 2025 - MarketScreener
Cingulate Provides Management Team Update - GlobeNewswire
Leadership Change: Cingulate Appoints CFO Jennifer Callahan as Interim CEO Amid ADHD Drug FDA Review - Stock Titan
Analysts Spot Bullish Divergence in Cingulate Inc.Dividend Hike & Free Fast Entry Momentum Trade Alerts - newsyoung.net
KC-area public company CEO faces felony charge for choking his girlfriend - FOX4KC.com
Can Cingulate Inc. deliver consistent EPS growthFed Meeting & Stepwise Trade Execution Plans - classian.co.kr
Investors Hope for Bounce in Cingulate Inc. Equity Warrant After SelloffFree Access to Community - beatles.ru
Cingulate terminates COO one day after submitting drug for FDA approval - The Business Journals
Analyzing drawdowns of Cingulate Inc. with statistical toolsTrade Ideas Based on Fundamental Metrics - Newser
Why Cingulate Inc. Equity Warrant is moving todayFree Chart Driven High Reward Trading Setup - Newser
Identifying reversal signals in Cingulate Inc. Equity WarrantAI Powered Buy Point Forecast Planner - Newser
How to read the order book for Cingulate Inc.Free Trade Scanner With Buy Zone Alerts - Newser
Smart tools for monitoring Cingulate Inc.’s price actionFree Short Term Setup With Predictive Chart - Newser
Does Cingulate Inc. Equity Warrant show high probability of reboundFree Triple Return Setup with Risk Control - Newser
Is Cingulate Inc. Equity Warrant reversing from oversold territoryReal Time Stock Movement and Alerts - Newser
Understanding Cingulate Inc.’s price movementFree Pattern Alert With ROI Driven Strategy - Newser
What technical models suggest about Cingulate Inc.’s comebackTechnical Insight Guide for Safer Trades - Newser
Using R and stats models for Cingulate Inc. Equity Warrant forecastingSwing Reversal Forecast Based on Patterns - Newser
Using data filters to optimize entry into Cingulate Inc. Equity WarrantEntry Timing with Downside Risk Analysis - Newser
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301 - TipRanks
What momentum shifts mean for Cingulate Inc.Swing Trade Timing with Daily Forecast - Newser
Cingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy Rating - TipRanks
Cingulate submits CTx-1301 NDA to FDA - TipRanks
Cingulate Inc Submits NDA for ADHD Treatment - TipRanks
Cingulate submits NDA for ADHD treatment to FDA By Investing.com - Investing.com Canada
Cingulate submits NDA for ADHD treatment to FDA - Investing.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):